6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$27M | — | — | -$31M | — | $29M |
| 2024 | — | -$37M | — | — | -$29M | — | $26M |
| 2023 | $675000 | -$31M | 0.0% | -3077.6% | -$18M | — | — |
| 2022 | $951000 | -$18M | 0.0% | -1898.2% | -$16M | — | $455000 |
| 2021 | — | -$10M | — | — | -$6M | — | $17M |
| 2020 | — | -$2M | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$13M | — | — | -$6M | — | $37M |
| Dec '25 | — | -$15M | — | — | -$8M | — | $29M |
| Sep '25 | — | -$6M | — | — | -$6M | — | $43M |
| Jun '25 | — | -$6M | — | — | -$8M | — | $22M |
| Mar '25 | — | $570000 | — | — | -$9M | — | $20M |
| Dec '24 | — | -$22M | — | — | -$7M | — | $26M |
| Sep '24 | — | -$4M | — | — | -$9M | — | — |
| Jun '24 | — | $10M | — | — | -$6M | — | — |
| Mar '24 | — | -$21M | — | — | -$6M | — | — |
| Dec '23 | $0 | -$8M | — | — | -$4M | — | — |
| Sep '23 | $0 | -$4M | — | — | -$4M | — | $14M |
| Jun '23 | $0 | -$4M | — | — | — | — | $19M |
| Mar '23 | $675000 | -$15M | 0.0% | -622.5% | — | — | $24M |
| Dec '22 | $0 | -$5M | — | — | -$6M | — | $455000 |
| Sep '22 | $951000 | -$6M | 0.0% | -584.0% | -$4M | — | $7M |
| Jun '22 | — | -$4M | — | — | -$3M | — | $11M |
| Mar '22 | — | -$4M | — | — | -$3M | — | $14M |
| Dec '21 | — | -$3M | — | — | — | — | $17M |
| Sep '21 | — | -$5M | — | — | — | — | $18M |
| Jun '21 | — | -$1M | — | — | — | — | $1000 |
How the market has priced UNCY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Unicycive Therapeutics, Inc.'s revenue has declined 29.0% per year. These are computed facts, not advice.
As of FY2025, Unicycive Therapeutics, Inc. reported — of total debt against $29M of cash; operating income covered interest expense -415.7×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.